| 2026-08-17 | 8-K | Form 8-K, Item 1.01 |
| 2026-08-14 | Press release | BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder B |
| 2026-08-13 | Press release | BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder |
| 2026-08-11 | Press release | BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-08-10 | Press release | BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates |
| 2026-08-10 | Press release | 2026 Q2 Press Release |
| 2026-08-10 | 8-K | Form 8-K, Item 2.02 results |
| 2026-08-10 | 10-Q | Form 10-Q for the quarter ended Jun 30 |
| 2026-08-03 | Press release | BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on at 4:30 pm ET |
| 2026-07-22 | Press release | BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1 |
| 2026-07-22 | 8-K | Form 8-K, Item 8.01 |
| 2026-07-10 | Press release | BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-07-02 | Press release | Download , Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM, July 2 |
| 2026-07-02 | Press release | Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM |
| 2026-07-02 | 8-K | Form 8-K, Item 1.01 |
| 2026-07-01 | Press release | Download , BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches, (o |
| 2026-07-01 | Press release | BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches |
| 2026-06-28 | Press release | Download , BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infi |
| 2026-06-28 | Press release | BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in |
| 2026-06-26 | 8-K | Form 8-K, Item 5.02 |
| 2026-06-23 | Press release | BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-06-22 | Press release | Download , BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living wit |
| 2026-06-22 | Press release | BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondrop |
| 2026-06-03 | Deck | Investor presentation · Jun 2026 |
| 2026-05-27 | Press release | Download , BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9, (opens |
| 2026-05-27 | Press release | BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9 |
| 2026-05-27 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-13 | 8-K | Form 8-K, Item 8.01 |
| 2026-05-12 | Press release | Download , BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1, (opens in new wind |
| 2026-05-12 | Press release | BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1 |
| 2026-05-11 | Press release | Download , Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpa |
| 2026-05-11 | Press release | Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worse |
| 2026-05-08 | Press release | BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) |
| 2026-05-08 | 8-K | Form 8-K, Item 1.01 |
| 2026-05-07 | Press release | BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates |
| 2026-05-07 | Press release | BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates |
| 2026-05-07 | Press release | Press release · Q1 2026 · May 2026 |
| 2026-05-07 | 8-K | Form 8-K, Item 2.02 results |
| 2026-05-07 | 10-Q | Form 10-Q for the quarter ended Mar 31 |
| Transcript | Q1 FY26 earnings call transcript |